• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Bitwise Announces Updates to ETF Lineup

    6/30/26 4:01:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IMRA alert in real time by email

    SAN FRANCISCO, June 30, 2026 /PRNewswire/ -- Bitwise Asset Management, the global crypto asset manager with $11 billion in client assets (As of April 1, 2026), plans to close and liquidate the Bitwise COIN Option Income Strategy ETF (ICOI), Bitwise MARA Option Income Strategy ETF (IMRA), Bitwise MSTR Option Income Strategy ETF (IMST), Bitwise GME Option Income Strategy ETF (IGME), Bitwise CRCL Option Income Strategy ETF (ICRC), and Bitwise Ethereum Option Income Strategy ETF (IETH).

    Bitwise Logo

    Ticker

    ETF Name

    Listing

    Exchange

    Last Day to

    Purchase

    Creation

    Units

    Last Day of

    Trading

    Final NAV

    Calculation

    Date

    Liquidation Date

    ICOI

    Bitwise COIN

    Option Income

    Strategy ETF

    NYSE Arca

    July 31,

    2026

    July 31,

    2026

    August 9, 2026

    August 10, 2026

    IMRA

    Bitwise MARA

    Option Income

    Strategy ETF

    NYSE Arca

    July 31,

    2026

    July 31,

    2026

    August 9, 2026

    August 10, 2026

    IMST

    Bitwise MSTR

    Option Income

    Strategy ETF

    NYSE Arca

    July 31,

    2026

    July 31,

    2026

    August 9, 2026

    August 10, 2026

    IGME

    Bitwise GME

    Option Income

    Strategy ETF

    NYSE Arca

    July 31,

    2026

    July 31,

    2026

    August 9, 2026

    August 10, 2026

    ICRC

    Bitwise CRCL

    Option Income

    Strategy ETF

    NYSE Arca

    July 31,

    2026

    July 31,

    2026

    August 9, 2026

    August 10, 2026

    IETH

    Bitwise

    Ethereum

    Option Income

    Strategy ETF

    NYSE Arca

    July 31,

    2026

    July 31,

    2026

    August 9, 2026

    August 10, 2026

    Shareholders who do not sell their shares of the ETFs by Friday, July 31, 2026, will have their shares automatically redeemed for cash based on each ETF's net asset value (NAV). The redemption is expected to be provided to shareholders through their brokers or other financial intermediaries on or around Monday, August 10, 2026.

    About Bitwise

    Bitwise Asset Management is a global crypto asset manager with more than $11 billion in client assets and a suite of 70 investment products spanning ETFs, staking, vaults, custom option income SMAs, tokenized funds, and private funds. The firm has an eight-year track record and today serves some of the world's leading institutional investors, crypto exchanges, digital asset treasury companies, and high-net-worth individuals. Bitwise also works with more than 5,500 private wealth teams, RIAs, and family offices, and over 20 banks and broker-dealers.

    Risks and Important Information

    Carefully consider a Fund's investment objectives, risk factors, charges, and expenses before investing. This and additional information can be found in each Fund's full or summary prospectus, which may be obtained by visiting: for ICOI, icoietf.com; for ICRC, icrcetf.com; for IETH, iethetf.com; for IGME, igmeetf.com; for IMRA, imraetf.com; for IMST, imstetf.com. Investors should read it carefully before investing.

    Investing involves risk, including the possible loss of principal. There is no guarantee or assurance that a Fund's methodology will result in the Fund achieving positive investment returns or outperforming other investment products.

    The technology relating to crypto assets and blockchain is new and developing. Trading in crypto assets or crypto asset derivatives comes with significant risks, including volatile market price swings or flash crashes, market manipulation, and cybersecurity risks and risk of losing principal or all of your investment. In addition, crypto asset markets and exchanges are not regulated with the same controls or customer protections available in equity, option, futures, or foreign exchange investing.

    Bitwise ETFs are distributed by Foreside Fund Services, LLC, which is not affiliated with Bitwise or its affiliates.

    Media Contact

    Tova Kaufmann

    pr@bitwiseinvestments.com

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bitwise-announces-updates-to-etf-lineup-302814903.html

    SOURCE Bitwise Asset Management

    Get the next $IMRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMRA

    DatePrice TargetRatingAnalyst
    1/6/2022$12.00 → $4.00Equal-Weight
    Morgan Stanley
    11/30/2021$10.00Buy
    HC Wainwright & Co.
    8/11/2021$33.00 → $12.00Overweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $IMRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley reiterated coverage on Imara with a new price target

    Morgan Stanley reiterated coverage of Imara with a rating of Equal-Weight and set a new price target of $4.00 from $12.00 previously

    1/6/22 10:34:33 AM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    HC Wainwright & Co. initiated coverage on Imara with a new price target

    HC Wainwright & Co. initiated coverage of Imara with a rating of Buy and set a new price target of $10.00

    11/30/21 7:23:31 AM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Imara downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Imara from Overweight to Equal-Weight and set a new price target of $12.00 from $33.00 previously

    8/11/21 6:17:27 AM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMRA
    SEC Filings

    View All

    SEC Form 144 filed by IMARA Inc.

    144 - Enliven Therapeutics, Inc. (0001672619) (Subject)

    2/15/24 5:04:57 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by IMARA Inc.

    144 - Enliven Therapeutics, Inc. (0001672619) (Subject)

    12/20/23 6:06:54 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by IMARA Inc.

    144 - Enliven Therapeutics, Inc. (0001672619) (Subject)

    12/19/23 5:27:50 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bitwise Announces Updates to ETF Lineup

    SAN FRANCISCO, June 30, 2026 /PRNewswire/ -- Bitwise Asset Management, the global crypto asset manager with $11 billion in client assets (As of April 1, 2026), plans to close and liquidate the Bitwise COIN Option Income Strategy ETF (ICOI), Bitwise MARA Option Income Strategy ETF (IMRA), Bitwise MSTR Option Income Strategy ETF (IMST), Bitwise GME Option Income Strategy ETF (IGME), Bitwise CRCL Option Income Strategy ETF (ICRC), and Bitwise Ethereum Option Income Strategy ETF (IETH). TickerETF NameListing ExchangeLast Day toPurchaseCreationUnitsLast Day ofTradingFinal NAVCalculationDateLiquidation DateICOIBitwise COINOption Inco

    6/30/26 4:01:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, June 25, 2026 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH. FundTickerDistribution Per ShareDistributionRate30-Day SECYieldReturn of CapitalEx-Date / Record DatePayment Date1-Month Return1-Year ReturnSince InceptionReturn*Bitwise COINOption Income Strategy ETFICOI$0.1676820.00 %0.00 %100.00 %6/26/20266/30/2026-11.80 %-51.38 %-29.37 %Bitwise MARAOption Income Strategy ETFIMRA$0.119568.44 %0.00 %100.00 %6/26/20266/30/2026-3.92 %-34.66 %-19.84 %Bitwise MSTROption

    6/25/26 4:49:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, May 21, 2026 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH. FundTickerDistribution Per ShareDistribution Rate30-Day SEC YieldReturn of CapitalEx-Date / Record DatePayment Date1-Month Return1-Year ReturnSince InceptionReturn*Bitwise COINOption Income Strategy ETFICOI$0.2566025.37 %0.00 %100.00 %5/22/20265/27/20262.41 %-35.98 %-20.61 %Bitwise MARAOption Income Strategy ETFIMRA$0.1710111.93 %0.00 %100.00 %5/22/2026

    5/21/26 4:01:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    5am Partners Vi, Llc sold $12,292,500 worth of shares (825,000 units at $14.90) (SEC Form 4)

    4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

    2/16/24 4:15:31 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Phillips Andrew John

    4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

    2/15/24 9:04:08 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Patel Anish

    4 - Enliven Therapeutics, Inc. (0001672619) (Issuer)

    2/15/24 9:02:21 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMRA
    Financials

    Live finance-specific insights

    View All

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, June 25, 2026 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH. FundTickerDistribution Per ShareDistributionRate30-Day SECYieldReturn of CapitalEx-Date / Record DatePayment Date1-Month Return1-Year ReturnSince InceptionReturn*Bitwise COINOption Income Strategy ETFICOI$0.1676820.00 %0.00 %100.00 %6/26/20266/30/2026-11.80 %-51.38 %-29.37 %Bitwise MARAOption Income Strategy ETFIMRA$0.119568.44 %0.00 %100.00 %6/26/20266/30/2026-3.92 %-34.66 %-19.84 %Bitwise MSTROption

    6/25/26 4:49:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, May 21, 2026 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH. FundTickerDistribution Per ShareDistribution Rate30-Day SEC YieldReturn of CapitalEx-Date / Record DatePayment Date1-Month Return1-Year ReturnSince InceptionReturn*Bitwise COINOption Income Strategy ETFICOI$0.2566025.37 %0.00 %100.00 %5/22/20265/27/20262.41 %-35.98 %-20.61 %Bitwise MARAOption Income Strategy ETFIMRA$0.1710111.93 %0.00 %100.00 %5/22/2026

    5/21/26 4:01:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Bitwise Announces Monthly Distributions for IMST, ICOI, IMRA, IGME, ICRC, and IETH

    SAN FRANCISCO, April 23, 2026 /PRNewswire/ -- Bitwise Asset Management, a leading crypto asset manager, today announced the monthly distributions for its suite of Option Income Strategy ETFs: IMST, ICOI, IMRA, IGME, ICRC, and IETH. FundTickerDistribution Per ShareDistribution Rate30-Day SEC YieldReturn of CapitalEx-Date / Record DatePayment Date1-Month Return1-Year ReturnSince InceptionReturn*Bitwise COINOption Income Strategy ETFICOI$0.2544725.40 %0.00 %100.00 %4/24/20264/28/2026-4.73 %-28.24 %-24.19 %Bitwise MARAOption Income Strategy ETFIMRA$0.1476311.25 %0.00 %100.00 %4/24/2

    4/23/26 5:06:00 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMRA
    Leadership Updates

    Live Leadership Updates

    View All

    Imara to Report Data Demonstrating the Potential of Tovinontrine (IMR-687) for the Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)

    Preclinical data from three different mouse models of HFpEF to be presented at American Heart Association (AHA) Scientific Sessions HFpEF development to be led by cardiologist Toni Bransford, M.D., FACC, FASE Imara's new Vice President of Clinical Development BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, announced data today in three preclinical mouse models of heart failure with preserved ejection fraction (HFpEF) treated with tovinontrine (IMR-687). Sele

    11/8/21 7:00:00 AM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Imara Announces Appointment of Laura A. Williams, M.D., MPH to Board of Directors

    BOSTON, June 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (NASDAQ:IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the election of Laura A. Williams, M.D., MPH to its Board of Directors. Dr. Williams brings 25 years of early-to-late-stage drug development experience across multiple therapeutic areas, as well as expertise in patient advocacy to Imara. "We're thrilled to welcome Dr. Williams to our Board," said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara. "In addition to her significant experience leading clinical

    6/30/21 7:00:00 AM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Imara Announces the Appointment of Kenneth Attie, M.D. as Chief Medical Officer

    BOSTON, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the appointment of Kenneth Attie, M.D. as Senior Vice President and Chief Medical Officer. Dr. Attie joins Imara with over 30 years of experience within academia and the biopharmaceutical industry, most recently at Acceleron Pharma, Inc. where he led global clinical development efforts that led to the recent FDA and EMA approvals of a new treatment for patients with rare anemias, including beta-thalassemia.  “We are exc

    1/20/21 7:00:00 AM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by IMARA Inc. (Amendment)

    SC 13D/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

    2/16/24 4:15:28 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by IMARA Inc. (Amendment)

    SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

    2/14/24 8:53:21 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by IMARA Inc. (Amendment)

    SC 13G/A - Enliven Therapeutics, Inc. (0001672619) (Subject)

    2/14/24 4:58:16 PM ET
    $IMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care